Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora

Drmić, Ivan Domagoj

prikaz prve stranice dokumenta Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora

doctoral thesis

Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora

Zagreb: University of Zagreb, School of Medicine, 2015. urn:nbn:hr:105:379838

Drmić, Ivan Domagoj

University of Zagreb
School of Medicine

Cite this document

APA 6th Edition

Drmić, I. D. (2015). Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora (Doctoral thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:379838

MLA 8th Edition

Drmić, Ivan Domagoj. "Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora ." Doctoral thesis, University of Zagreb, School of Medicine, 2015. https://urn.nsk.hr/urn:nbn:hr:105:379838

Chicago 17th Edition

Harvard

Drmić, I. D. (2015). 'Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora ', Doctoral thesis, University of Zagreb, School of Medicine, accessed 18 April 2024, https://urn.nsk.hr/urn:nbn:hr:105:379838

Vancouver

Drmić ID. Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora [Doctoral thesis]. Zagreb: University of Zagreb, School of Medicine; 2015 [cited 2024 April 18] Available at: https://urn.nsk.hr/urn:nbn:hr:105:379838

IEEE

I. D. Drmić, "Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora ", Doctoral thesis, University of Zagreb, School of Medicine, Zagreb, 2015. Available at: https://urn.nsk.hr/urn:nbn:hr:105:379838

Cite this item: https://urn.nsk.hr/urn:nbn:hr:105:379838

Please login to the repository to save this object to your list.

Metadata

Title	Protektivan učinak pentadekapeptida BPC 157 na cijeljenje oštećenja želuca, duodenuma, jetara i mozga uzrokovanih visokom dozom celekoksiba u štakora
Title (english)	Protective effect of pentadecapeptide BPC 157 on healing of gastric, duodenal, liver and brain lesions induced by high dose of celecoxib in rats
Author	Ivan Domagoj Drmić MBZ: 342491
Mentor	Predrag Sikirić (mentor)
Committee member	nije dostupno (član povjerenstva)
Granter	University of Zagreb School of Medicine Zagreb
Defense date and country	2015-06-19, Croatia
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Basic Medical Sciences
Universal decimal classification (UDC)	61 - Medical sciences
Abstract	Pomoću terapije BPC-om 157 (poznatom po inhibiciji gastrointestinalne, jetrene i moždane toksičnosti izazvane neselektivnim NSAIDs-ima) i L-argininom, pokušali smo razlučiti punu kompleksnost lezija (želučanih, jetrenih, moždanih) nakon administracije visoke doze celekoksiba; pogoršanje (koje oponaša pokušaj za oslobađanje od boli (npr. selektivni NSAID kao inhibitor enzima COX-2) i blokada enzima NOS-a (L-NAME)) zajedno sa mogućom terapijom iza svih ovih fenomena. U štakora soja Wistar, celekoksib (1g/kg tj.t. i.p.) je inducirao teške želučane lezije sa porastom oštećenja protokom vremena sa 24 na 48 sati, uz održanu razinu oštećenja jetre i mozga. Sva ta oštećenja su bila dodatno povećana uz primjenu L-NAME (5 mg/kg TT i.p. odmah nakon celekoksiba). Kao potrebni dokaz specifičnog upliva (Larginin, L-NAME+L-arginin), L-arginin (100 mg/kg tj.t. i.p. odmah nakon celekoksiba) je pokazao ograničeni korisni učinak (t.j. samo nakon 48 sati) dok je istovremeno zajedničko davanje L-arginina i L-NAME smanjuje pogoršanje izazvano L-NAME-om do lezija sličnih onima koje vidimo kod kontrolnih životinja tretiranih celekoksibom i nakon 24 i nakon 48 sati. Dakle, L-arginin je bio konzistentno više aktivan kad je dan zajedno sa L-NAME-om (stoga, više protiv L-NAME, manje protiv celekoksiba, manje protiv inhibicije enzima COX-2, inhibicija COX-2 enzima ostaje većinom sačuvana). Suprotno tome, BPC 157 dan samostalno (10 >g, 10 ng/kg tj.t. i.p. odmah nakon celekoksiba) umanjuje lezije izazvane celekoksibom i nakon 24 i nakon 48 sati. Poput toga, isti korisni učinak je bio konzistentno vidljiv kod svih inače povećanih negativnih okolnosti pri aplikaciji celekoksiba i L-NAME, kao i u svim grupama koje su primale BPC 157 (L-arginin+BPC 157; L-NAME+BPC 157; L-NAME+L-arginin+BPC 157). Stoga ovi nalazi pokazuju da se BPC 157 može jednako suprotstaviti inhibiciji enzima COX-2 (suprotstavljanje štetnom učinku celekoksiba u svim lezijama) kao i dodatnoj blokadi enzima NOS (suprostavljanje zajedničkom štetnom učinku celekoksiba i L-NAME).
Abstract (english)	With therapy with BPC 157 (known to inhibit nonselective NSAIDs- gastrointestinal, liver and brain-toxicity) and L-arginine, we attempted to discriminate the full complexity of lesions (stomach, liver, brain) after high dose celecoxib administration; the aggravation (that mimics attempt to relieve pain (i.e., selective NSAID as COX-2 inhibition) and NOS-blockade (L-NAME)) along with a possible therapy success and the mechanism(s) behind all of these phenomena. In Wistar rats celecoxib (1g/kg bw ip) induced severe gastric lesions with gradual increase from 24h to 48h after administration, and sustained level of liver and brain lesions. All these lesions were aggravated by L-NAME (5 mg/kg bw ip immediately after celecoxib). As the needed proof of NO-system specific involvement, (L-arginine; L-NAME+L-arginine), Larginine (100 mg/kg bw ip immediately after celecoxib) exhibited a limited beneficial effect (i.e., only after 48h) while L-NAME+L-arginine protocol turned down L-NAMEaggravation to the control-celecoxib presentation at both 24h and 48h period. Thus, L-arginine was consistently more active given together with L-NAME (thus, more against L-NAME, less against celecoxib, less against COX-2 inhibition, COX-2- inhibition remains mostly preserved). Contrary, given alone BPC 157 (10 >g, 10 ng/kg bw ip immediately after celecoxib) completely turned down lesions induced by celecoxib, both at 24h and 48h. Likewise, the same beneficial effect was consistently evident in all increasingly negative circumstances of celecoxib and L-NAME application and in all BPC 157-groups (L-arginine+BPC 157; L-NAME+BPC 157; LNAME+ L-arginine+BPC 157). Thereby, these findings evidenced that BPC 157 may equally counteract both COX-2 inhibition (celecoxib-noxious effect on all lesions counteracted) and additional NOS-blockade (celecoxib+L-NAME-noxious effect also equally counteracted).
Keywords
Keywords (english)
Language	croatian
URN:NBN	urn:nbn:hr:105:379838
Study programme	Title: Neuroscience Study programme type: university Study level: postgraduate Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstva (doktor/doktorica znanosti, područje biomedicine i zdravstva)
Type of resource	Text
Extent	90 str.
File origin	Born digital
Access conditions	Open access
Terms of use
Repository	Dr Med - University of Zagreb School of Medicine Digital Repository
Created on	2023-05-05 08:39:58

Nacionalna i sveučilišna knjižnica u Zagrebu

Dabar